{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:44:42Z","timestamp":1790844282262,"version":"4.1.0"},"reference-count":83,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,6,13]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>IBR+VEN combination was designed to overcome resistance to IBR, but CLL and MCL samples ex vivo show resistance even to this combination. Microenvironmental agonists (IL-10, soluble CD40L, CpG-ODN) generate resistance via NF-\u03baB\u2013dependent expression of Mcl-1\/Bcl-xL\/survivin.<\/jats:p>","DOI":"10.1182\/bloodadvances.2016004176","type":"journal-article","created":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T15:13:21Z","timestamp":1568042001000},"page":"933-946","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":107,"title":["Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL"],"prefix":"10.1182","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7239-5246","authenticated-orcid":false,"given":"Kallesh D.","family":"Jayappa","sequence":"first","affiliation":[{"name":"Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, VA;"},{"name":"Beirne B. Carter Center for Immunology Research, Charlottesville, VA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig A.","family":"Portell","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, School of Medicine,"},{"name":"Cancer Center, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki L.","family":"Gordon","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, VA;"},{"name":"Beirne B. Carter Center for Immunology Research, Charlottesville, VA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Capaldo","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Bekiranov","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Axelrod","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, VA;"},{"name":"Cancer Center, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Kyle","family":"Brett","sequence":"additional","affiliation":[{"name":"Medical Oncology, Utica Park Clinic, Tulsa, OK; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia D.","family":"Wulfkuhle","sequence":"additional","affiliation":[{"name":"Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa I.","family":"Gallagher","sequence":"additional","affiliation":[{"name":"Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel F.","family":"Petricoin","sequence":"additional","affiliation":[{"name":"Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Bender","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, VA;"},{"name":"Beirne B. Carter Center for Immunology Research, Charlottesville, VA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Williams","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, School of Medicine,"},{"name":"Cancer Center, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4551-123X","authenticated-orcid":false,"given":"Michael J.","family":"Weber","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, VA;"},{"name":"Beirne B. Carter Center for Immunology Research, Charlottesville, VA;"},{"name":"Cancer Center, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2017,6,7]]},"reference":[{"issue":"16","key":"2019111618035472200_B1","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"issue":"25","key":"2019111618035472200_B2","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111618035472200_B3","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2019111618035472200_B4","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2019111618035472200_B5","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"10020","key":"2019111618035472200_B6","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"issue":"18","key":"2019111618035472200_B7","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2016-05-716977","article-title":"Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience","volume":"128","author":"Mato","year":"2016","journal-title":"Blood"},{"issue":"18","key":"2019111618035472200_B8","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood-2016-09-739664","article-title":"BCR inhibitor failure in CLL: an unmet need","volume":"128","author":"Jain","year":"2016","journal-title":"Blood"},{"key":"2019111618035472200_B9","article-title":"Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib [published online ahead of print 7 February 2017]","author":"Jain","journal-title":"Cancer"},{"issue":"13","key":"2019111618035472200_B10","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J Clin Oncol"},{"issue":"13","key":"2019111618035472200_B11","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","article-title":"Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib","volume":"125","author":"Jain","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2019111618035472200_B12","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","article-title":"Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes","volume":"26","author":"Cheah","year":"2015","journal-title":"Ann Oncol"},{"issue":"24","key":"2019111618035472200_B13","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMc1402716","article-title":"Ibrutinib resistance in chronic lymphocytic leukemia [published correction appears in N Engl J Med. 2014;370(26):2547]","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111618035472200_B14","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discov"},{"issue":"24","key":"2019111618035472200_B15","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111618035472200_B16","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1182\/blood-2015-11-681460","article-title":"Pathogenic role of B-cell receptor signaling and canonical NF-\u03baB activation in mantle cell lymphoma","volume":"128","author":"Saba","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2019111618035472200_B17","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","article-title":"Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia","volume":"129","author":"Ahn","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2019111618035472200_B18","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/nm.3392","article-title":"Tumor adaptation and resistance to RAF inhibitors","volume":"19","author":"Lito","year":"2013","journal-title":"Nat Med"},{"issue":"10","key":"2019111618035472200_B19","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1158\/1078-0432.CCR-13-1081","article-title":"Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer","volume":"20","author":"Johnson","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2019111618035472200_B20","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1158\/1535-7163.MCT-10-1033","article-title":"Compensatory pathways induced by MEK inhibition are effective drug targets for combination therapy against castration-resistant prostate cancer","volume":"10","author":"Gioeli","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"2019111618035472200_B21","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1158\/2159-8290.CD-12-0012","article-title":"Circumventing cancer drug resistance in the era of personalized medicine","volume":"2","author":"Garraway","year":"2012","journal-title":"Cancer Discov"},{"issue":"1","key":"2019111618035472200_B22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"issue":"2","key":"2019111618035472200_B23","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/leu.2013.249","article-title":"Combinatorial drug screening identifies synergistic co-targeting of Bruton\u2019s tyrosine kinase and the proteasome in mantle cell lymphoma","volume":"28","author":"Axelrod","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"2019111618035472200_B24","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"4","key":"2019111618035472200_B25","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1158\/1078-0432.CCR-15-2921","article-title":"Cell-intrinsic determinants of ibrutinib-induced apoptosis in chronic lymphocytic leukemia","volume":"23","author":"Amin","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2019111618035472200_B26","doi-asserted-by":"crossref","first-page":"7632","DOI":"10.18632\/oncotarget.2939","article-title":"Co-culture of primary CLL cells with bone marrow mesenchymal cells, CD40 ligand and CpG ODN promotes proliferation of chemoresistant CLL cells phenotypically comparable to those proliferating in vivo","volume":"6","author":"Purroy","year":"2015","journal-title":"Oncotarget"},{"issue":"2","key":"2019111618035472200_B27","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1158\/1078-0432.CCR-12-1922","article-title":"In vitro sensitivity of CLL cells to fludarabine may be modulated by the stimulation of Toll-like receptors","volume":"19","author":"Fonte","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2019111618035472200_B28","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4049\/jimmunol.1401854","article-title":"Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells","volume":"194","author":"Tan","year":"2015","journal-title":"J Immunol"},{"issue":"24","key":"2019111618035472200_B29","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1182\/blood-2016-06-720490","article-title":"Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma","volume":"128","author":"Chiron","year":"2016","journal-title":"Blood"},{"issue":"25","key":"2019111618035472200_B30","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1182\/blood-2015-10-675009","article-title":"BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199","volume":"127","author":"Bojarczuk","year":"2016","journal-title":"Blood"},{"issue":"8","key":"2019111618035472200_B31","first-page":"e302","article-title":"Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors","volume":"100","author":"Thijssen","year":"2015","journal-title":"Haematologica"},{"issue":"24","key":"2019111618035472200_B32","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1182\/blood-2016-10-745307","article-title":"Neighborhood imbalances: overcoming MCL drug resistance","volume":"128","author":"Pagel","year":"2016","journal-title":"Blood"},{"issue":"36","key":"2019111618035472200_B33","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1038\/onc.2014.403","article-title":"The tumor microenvironment shapes hallmarks of mature B-cell malignancies","volume":"34","author":"Shain","year":"2015","journal-title":"Oncogene"},{"issue":"3","key":"2019111618035472200_B34","doi-asserted-by":"crossref","first-page":"901","DOI":"10.4049\/jimmunol.1403189","article-title":"TLR-9 and IL-15 synergy promotes the in vitro clonal expansion of chronic lymphocytic leukemia B cells","volume":"195","author":"Mongini","year":"2015","journal-title":"J Immunol"},{"issue":"5","key":"2019111618035472200_B35","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1365-2141.2012.09191.x","article-title":"Mimicking the tumour microenvironment: three different co-culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells","volume":"158","author":"Hamilton","year":"2012","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111618035472200_B36","doi-asserted-by":"crossref","first-page":"e60370","DOI":"10.1371\/journal.pone.0060370","article-title":"A combination of cytokines rescues highly purified leukemic CLL B-cells from spontaneous apoptosis in vitro","volume":"8","author":"Ghamlouch","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"2019111618035472200_B37","doi-asserted-by":"crossref","first-page":"6713","DOI":"10.4049\/jimmunol.177.10.6713","article-title":"CXC chemokine ligand 13 and CC chemokine ligand 19 cooperatively render resistance to apoptosis in B cell lineage acute and chronic lymphocytic leukemia CD23+CD5+ B cells","volume":"177","author":"Chunsong","year":"2006","journal-title":"J Immunol"},{"issue":"11","key":"2019111618035472200_B38","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1038\/leu.2009.145","article-title":"Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles","volume":"23","author":"Plander","year":"2009","journal-title":"Leukemia"},{"issue":"2","key":"2019111618035472200_B39","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2003-02-0540","article-title":"Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway","volume":"103","author":"Kern","year":"2004","journal-title":"Blood"},{"issue":"36","key":"2019111618035472200_B40","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1038\/onc.2010.248","article-title":"Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40\/TLR9 triggering","volume":"29","author":"Tromp","year":"2010","journal-title":"Oncogene"},{"key":"2019111618035472200_B41","doi-asserted-by":"crossref","first-page":"290","DOI":"10.2119\/molmed.2012.00303","article-title":"Chronic lymphocytic leukemia cells in a lymph node microenvironment depict molecular signature associated with an aggressive disease","volume":"20","author":"Mittal","year":"2014","journal-title":"Mol Med"},{"issue":"2","key":"2019111618035472200_B42","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","article-title":"The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia","volume":"117","author":"Herishanu","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2019111618035472200_B43","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1182\/blood-2006-03-014001","article-title":"B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation","volume":"108","author":"Jahrsd\u00f6rfer","year":"2006","journal-title":"Blood"},{"issue":"7","key":"2019111618035472200_B44","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1084\/jem.20111644","article-title":"Serum from patients with SLE instructs monocytes to promote IgG and IgA plasmablast differentiation","volume":"209","author":"Joo","year":"2012","journal-title":"J Exp Med"},{"issue":"9","key":"2019111618035472200_B45","doi-asserted-by":"crossref","first-page":"e0138210","DOI":"10.1371\/journal.pone.0138210","article-title":"Systems analysis of adaptive responses to MAP kinase pathway blockade in BRAF mutant melanoma","volume":"10","author":"Capaldo","year":"2015","journal-title":"PLoS One"},{"issue":"11","key":"2019111618035472200_B46","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1158\/1535-7163.MCT-12-0461","article-title":"Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma","volume":"11","author":"Roller","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"2019111618035472200_B47","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"The toxicity of poisons applied jointly","volume":"26","author":"Bliss","year":"1939","journal-title":"Ann Appl Biol"},{"issue":"16","key":"2019111618035472200_B48","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1158\/1078-0432.CCR-14-2809","article-title":"Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia","volume":"21","author":"Cervantes-Gomez","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2019111618035472200_B49","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1158\/1535-7163.MCT-10-0725","article-title":"Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-kappaB signaling pathway","volume":"10","author":"Jane","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"2019111618035472200_B50","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","article-title":"Molecular mechanism and function of CD40\/CD40L engagement in the immune system","volume":"229","author":"Elgueta","year":"2009","journal-title":"Immunol Rev"},{"key":"2019111618035472200_B51","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1146\/annurev.immunol.19.1.683","article-title":"Interleukin-10 and the interleukin-10 receptor","volume":"19","author":"Moore","year":"2001","journal-title":"Annu Rev Immunol"},{"issue":"7","key":"2019111618035472200_B52","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nri1391","article-title":"Toll-like receptor signalling","volume":"4","author":"Akira","year":"2004","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"2019111618035472200_B53","doi-asserted-by":"crossref","first-page":"e72593","DOI":"10.1371\/journal.pone.0072593","article-title":"Protein kinase C beta mediates CD40 ligand-induced adhesion of monocytes to endothelial cells","volume":"8","author":"Wu","year":"2013","journal-title":"PLoS One"},{"key":"2019111618035472200_B54","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.brainres.2010.11.096","article-title":"IL-10 directly protects cortical neurons by activating PI-3 kinase and STAT-3 pathways","volume":"1373","author":"Sharma","year":"2011","journal-title":"Brain Res"},{"issue":"12","key":"2019111618035472200_B55","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","article-title":"Phosphatidylinositol 3-kinase-\u03b4 inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals","volume":"116","author":"Herman","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2019111618035472200_B56","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1158\/1535-7163.MCT-12-0767","article-title":"A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo","volume":"13","author":"Abulwerdi","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"17","key":"2019111618035472200_B57","doi-asserted-by":"crossref","first-page":"8014","DOI":"10.1158\/0008-5472.CAN-07-1343","article-title":"YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts [published correction appears in Cancer Res. 2012;72(15):3886]","volume":"67","author":"Nakahara","year":"2007","journal-title":"Cancer Res"},{"issue":"2","key":"2019111618035472200_B58","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/35055085","article-title":"Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL","volume":"3","author":"Degterev","year":"2001","journal-title":"Nat Cell Biol"},{"issue":"8","key":"2019111618035472200_B59","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1158\/1535-7163.MCT-14-0928","article-title":"MCL-1 is a key determinant of breast cancer cell survival: validation of MCL-1 dependency utilizing a highly selective small molecule inhibitor","volume":"14","author":"Xiao","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"2019111618035472200_B60","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood-2016-05-718494","article-title":"Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling","volume":"129","author":"Myklebust","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2019111618035472200_B61","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1182\/blood-2013-10-529610","article-title":"Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia","volume":"123","author":"Jia","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2019111618035472200_B62","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/annonc\/mdp006","article-title":"Cell-free circulating DNA in Hodgkin\u2019s and non-Hodgkin\u2019s lymphomas","volume":"20","author":"Hohaus","year":"2009","journal-title":"Ann Oncol"},{"issue":"10","key":"2019111618035472200_B63","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1002\/cncr.21816","article-title":"Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies","volume":"106","author":"Hock","year":"2006","journal-title":"Cancer"},{"issue":"1","key":"2019111618035472200_B64","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1182\/blood.V97.1.256","article-title":"Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome","volume":"97","author":"Fayad","year":"2001","journal-title":"Blood"},{"issue":"4","key":"2019111618035472200_B65","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood-2015-05-646935","article-title":"Integration of innate into adaptive immune responses in ZAP-70-positive chronic lymphocytic leukemia","volume":"127","author":"Wagner","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2019111618035472200_B66","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1158\/1078-0432.CCR-04-1890","article-title":"B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides","volume":"11","author":"Jahrsdorfer","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"20","key":"2019111618035472200_B67","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1182\/blood-2010-02-268375","article-title":"Mantle cell lymphoma activation enhances bortezomib sensitivity","volume":"116","author":"Brennan","year":"2010","journal-title":"Blood"},{"key":"2019111618035472200_B68","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood.V128.22.2025.2025","article-title":"Longitudinal assessment of CLL patients under ibrutinib treatment reveals maintained capacity to respond to microenvironmental stimuli through the Toll-like receptors","volume":"128","author":"Gounari","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2019111618035472200_B69","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.4049\/jimmunol.1302102","article-title":"Heterogeneous functional effects of concomitant B cell receptor and TLR stimulation in chronic lymphocytic leukemia with mutated versus unmutated Ig genes","volume":"192","author":"Chatzouli","year":"2014","journal-title":"J Immunol"},{"issue":"22","key":"2019111618035472200_B70","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.4346.4346","article-title":"Acalabrutinib increases mitochondrial priming and enhances venetoclax sensitivity in CLL cells [abstract]","volume":"128","author":"Deng","year":"2016","journal-title":"Blood"},{"issue":"23","key":"2019111618035472200_B71","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.490.490","article-title":"Ibrutinib therapy increases BCL-2 dependence and enhances sensitivity to venetoclax in CLL [abstract]","volume":"126","author":"Deng","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2019111618035472200_B72","doi-asserted-by":"crossref","first-page":"5630","DOI":"10.4049\/jimmunol.170.11.5630","article-title":"IKK beta plays an essential role in the phosphorylation of RelA\/p65 on serine 536 induced by lipopolysaccharide","volume":"170","author":"Yang","year":"2003","journal-title":"J Immunol"},{"issue":"1","key":"2019111618035472200_B73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/mutage\/gen056","article-title":"Signalling loops and linear pathways: NF-kappaB activation in response to genotoxic stress","volume":"24","author":"Brz\u00f3ska","year":"2009","journal-title":"Mutagenesis"},{"key":"2019111618035472200_B74","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/484537","article-title":"Constitutive NF-\u03baB activation underlines major mechanism of drug resistance in relapsed refractory diffuse large B cell lymphoma","volume-title":"Biomed Res Int","author":"Turturro","year":"2015"},{"issue":"1","key":"2019111618035472200_B75","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-\u03baB-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat Med"},{"issue":"1","key":"2019111618035472200_B76","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/hon.2251","article-title":"Concomitant high expression of Toll-like receptor (TLR) and B-cell receptor (BCR) signalling molecules has clinical implications in mantle cell lymphoma","volume":"35","author":"Akhter","year":"2017","journal-title":"Hematol Oncol"},{"issue":"1","key":"2019111618035472200_B77","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00109-013-1081-6","article-title":"RelB, together with RelA, sustains cell survival and confers proteasome inhibitor sensitivity of chronic lymphocytic leukemia cells from bone marrow","volume":"92","author":"Xu","year":"2014","journal-title":"J Mol Med (Berl)"},{"issue":"50","key":"2019111618035472200_B78","doi-asserted-by":"crossref","first-page":"7342","DOI":"10.1038\/sj.onc.1204926","article-title":"Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer","volume":"20","author":"Catz","year":"2001","journal-title":"Oncogene"},{"key":"2019111618035472200_B79","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/1471-2407-14-98","article-title":"Regulation of Mcl-1 by constitutive activation of NF-\u03baB contributes to cell viability in human esophageal squamous cell carcinoma cells","volume":"14","author":"Liu","year":"2014","journal-title":"BMC Cancer"},{"issue":"2","key":"2019111618035472200_B80","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/path.1768","article-title":"Expression of the NF-kappaB targets BCL2 and BIRC5\/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively","volume":"206","author":"Tracey","year":"2005","journal-title":"J Pathol"},{"issue":"4","key":"2019111618035472200_B81","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.4049\/jimmunol.165.4.1743","article-title":"The NF-kappa B cascade is important in Bcl-xL expression and for the anti-apoptotic effects of the CD28 receptor in primary human CD4+ lymphocytes","volume":"165","author":"Khoshnan","year":"2000","journal-title":"J Immunol"},{"issue":"4","key":"2019111618035472200_B82","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1182\/blood-2006-05-021683","article-title":"Differential Noxa\/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity","volume":"109","author":"Smit","year":"2007","journal-title":"Blood"},{"issue":"7626","key":"2019111618035472200_B83","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"}],"updated-by":[{"DOI":"10.1182\/bloodadvances.2017011148","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T00:00:00Z","timestamp":1503360000000}}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/14\/933\/877375\/advances004176.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/14\/933\/877375\/advances004176.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T18:04:29Z","timestamp":1573927469000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/1\/14\/933\/16198\/Microenvironmental-agonists-generate-de-novo"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,7]]},"references-count":83,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2017,6,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2016004176","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,7]]}}}